Clinical Trials (Gastrointestinal)

Research studies conducted with cancer patients are called clinical trials. As a cancer patient, you may take part in a clinical trial. Please see the links below for current open trials at UC San Francisco. 

CC#187015: A Phase 2 Study of Perioperative Immunotherapy in Patients with Colorectal Cancer and Resectable Hepatic Metastases
Contact: Marissa Gin (415) 476-3816: [email protected]
 
CC#214514: A Phase 1b/2 Study of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients with Advanced Gastrointestinal Malignancies (HERKULES-3)
Contact: Marin Pollak (415) 476-7974: [email protected]
 
CC# 214515: An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination with Belzutifan in Multiple Solid Tumors
Contact: Karen Zhang (415) 502-1877: [email protected]
Not currently enrolling
 
CC#22705: A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of GCC19CART for Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Contact: Cate Gwinn: [email protected]
 
CC#22454: A Phase 2 Basket Trial of Ulixertinib (BVD-523) in Combination with Hydroxychloroquine in Patients with Advanced Gastrointestinal Malignancies Harboring MAPK Pathway Mutations (BVD-523-HCQ)
Contact: Lauren Ford (415) 353-7284: [email protected]
Not yet enrolling
 
Colorectal Non-Therapeutic Studies
 
CC#134510: GIMP: Molecular Profiling in Gastrointestinal Malignancies
Contact: Dalila Stanfield (415) 476-2976: [email protected]
 
CC#204518: BESPOKE Study of ctDNA-Guided Therapy in Colorectal Cancer
Contact: Marin Pollak (415) 476-7974: [email protected]
 
CC#21456: Optimizing Intervention Tools to Improve Nutrition and Physical Activity for Colorectal Cancer Survivors (Tools To Be Fit)
Contact: Quincy Harris (415) 353-9544: [email protected] 
https://toolstobefit.eurekaplatform.org/
 
CC#214519: Evaluation of a Pilot Integrated Rectal Cancer Exercise Program (REP’s)
Contact: Banaz Shwan (415) 514-7285: [email protected]

AMC095: A Phase 1 Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors
Contact: Yuwen Jian [email protected]
Not currently enrolling
 
CC#19958: First-In-Human, Open-Label, Phase I Dose Escalation and Cohort Expansion Study of BB-1701 in Locally Advanced/Metastatic Her2 Expressing Solid Tumors
Contact: Kristy Tjokro: [email protected]  
Not currently enrolling
 
CC#18956: A Phase 1B Dose Escalation/Expansion Study of Abexinostat in Combination with Pembrolizumab in Patients with Advanced Solid Tumor Malignancies
Contact: Amrutha Sugetur: [email protected]
Not currently enrolling
 
CC#199511: A Phase 1/2 Study of CYT-0851 (a RAD51 inhibitor) in Patients with Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors
Contact: Yuwen Jian [email protected]
 
CC#209511: A first in human study of highly selective FGFR2 inhibitor, RLY-4008 in patients with intrahepatic cholangiocarcinoma (ICC)
Contact: Nela Pawlowska: [email protected]
Not currently enrolling
 
CC#209517: A Phase 1/2 Trial of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation
Contact: Phu Lam: [email protected]
Not currently enrolling
                                                                                                                                                  
CC#20958: A Phase 1 Study of ERK1/2 Inhibitor JSI-1187 Administered as Monotherapy and in Combination with Dabrafenib for the treatment of Advanced Solid Tumors with MAPK Pathway Mutations
Contact: Nela Pawlowksa: [email protected]
Not currently enrolling
 
CC#209515: A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE)
Contact: Yuwen Jian: [email protected]
 
CC#21951: LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-Randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients with an Advanced Solid Tumor 
Contact: Yuwen Jian: [email protected]
Not currently enrolling
 
CC#21704: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
Contact: Marissa Gin (415) 476-3816: [email protected]
 
CC#189515: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Sotorasib (AMG 510) Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and Sotorasib (AMG 510) Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreaK 100)
Contact: Maria Mir: [email protected] 

CC#217013: A Phase 1B, Open-Label, Dose-Escalation Study of the Safety of and Antigen-specific Immune Responses Elicited by VB10.NEO in Combination With Atezolizumab in Patients With Locally Advanced and Metastatic Tumors
Contact: Chris De Leon (415) 476-2958: [email protected]
 
CC#217015: Open-label, Multicenter, Phase 1b Clinical Trial to Evaluate the Safety and Efficacy of Autologous Claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma
Contact: Saba Saidi: [email protected]
 
CC#21704: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
Contact: Marissa Gin (415) 476-3816: [email protected]
 
CC#22454: A Phase 2 Basket Trial of Ulixertinib (BVD-523) in Combination with Hydroxychloroquine in Patients with Advanced Gastrointestinal Malignancies Harboring MAPK Pathway Mutations (BVD-523-HCQ)
Contact: Lauren Ford (415) 353-7284: [email protected]
Not yet enrolling

CC#197010: A Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in Patients with Advanced Mesothelin-Expressing Cancer
Contact: Saba Saidi: [email protected]
 
CC#174523: Multicenter Pilot Study of the Safety, Efficacy, and Immune Cell
Profiling in Advanced Hepatocellular Carcinoma (HCC) Patients Treated with the Combination of Sorafenib plus Nivolumab as First-Line of Systemic Therapy
Contact: Yasmin Alpoguz (415) 476-3755: [email protected]
 
CC#204517: A Phase Ib/II, Open-Label, Multicenter, Randomized, Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Advanced Liver Cancers (Morpheus-Liver)
Contact: Ashna Sethi (415) 353-1745: [email protected]
 
CC#194522: Phase II Trial of Durvalumab (MEDI4736) with/without Tremelimumab for Advanced Hepatocellular Carcinoma after Palliative Hypofractionated Radiotherapy
Contact: Luchia Andemicael (415) 476-8099: [email protected]
 
CC# 214515: An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination with Belzutifan in Multiple Solid Tumors
Contact: Karen Zhang (415) 502-1877: [email protected]
Not currently enrolling
 
CC#22454: A Phase 2 Basket Trial of Ulixertinib (BVD-523) in Combination with Hydroxychloroquine in Patients with Advanced Gastrointestinal Malignancies Harboring MAPK Pathway Mutations (BVD-523-HCQ)
Contact: Lauren Ford (415) 353-7284: [email protected]
Not yet enrolling
 
Hepatocellular and Biliary Tract Non-Therapeutic Studies
 
CC#124512: Banking of Human Biological Specimens for Hepatobiliary Cancer Research Studies: UCSF Hepatobiliary Tissue Bank and Registry
Contact: Karen Zhang (415) 502-1877: [email protected]
 
CC#174535: A 5-year Longitudinal Observational Study of the Natural History and Management of Patients With Hepatocellular Carcinoma (HCC)
Contact: Karen Zhang (415) 502-1877: [email protected]
 
CC#204516: A National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer (PLC)
Contact: Karen Zhang (415) 502-1877: [email protected]

CC#17705: A Pilot Study of Pembrolizumab and Liver Directed Therapy or Peptide Receptor Radionuclide Therapy for Patients with Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Metastases.
Contact: Chris De Leon (415) 476-2958: [email protected]
 
CC#197010: A Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in Patients With Advanced Mesothelin-Expressing Cancer
Contact: Saba Saidi: [email protected]
 
CC#187015: A Phase 2 Study of Perioperative Immunotherapy in Patients with Colorectal Cancer and Resectable Hepatic Metastases
Contact: Marissa Gin (415) 476-3816: [email protected]
 
CC#217013: A Phase 1B, Open-Label, Dose-Escalation Study of the Safety of and Antigen-specific Immune Responses Elicited by VB10.NEO in Combination With Atezolizumab in Patients With Locally Advanced and Metastatic Tumors
Contact: Chris De Leon (415) 476-2958: [email protected]
 
CC#22705: A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of GCC19CART for Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Contact: Cate Gwinn: [email protected]
 
CC#217015: Open-label, Multicenter, Phase 1b Clinical Trial to Evaluate the Safety and Efficacy of Autologous Claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma
Contact: Saba Saidi: [email protected]
 
CC#21704: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
Contact: Marissa Gin (415) 476-3816: [email protected]
 
CC#21705: Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
Contact: Saba Saidi: Saba.[email protected]
 
CC#21708: A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Contact: Saba Saidi: [email protected]
 
CC#19721: Phase II Study of Hypofractionated Radiation Therapy to Augment Immune Response in Patients with Metastatic Gastrointestinal Malignancies Progressing on Immune Therapy (ARM-GI)
Contact: Hewitt Chang (415) 514-1571: [email protected]
 
CC#194522: Phase II Trial of Durvalumab (MEDI4736) with/without Tremelimumab for Advanced Hepatocellular Carcinoma after Palliative Hypofractionated Radiotherapy
Contact: Luchia Andemicael (415) 476-8099: [email protected]

CC#17705: A Pilot Study of Pembrolizumab and Liver-Directed Therapy or Peptide Receptor Radionuclide Therapy for Patients with Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Metastases
Contact: Chris De Leon (415) 476-2958: [email protected]
 
A021602: Randomized, Double-Blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumors after Progression on Everolimus (CABINET)
Contact: Bryan Le (415) 502-6313: [email protected]
 
Neuroendocrine Tumors Non-Therapeutic Studies
 
CC#194520: e-NET: A Pilot Study Using a Web-Based Health Platform to Investigate Health-Related Quality of Life in Patients with Neuroendocrine Tumors
Contact: Farhana Moon: [email protected], [email protected]
https://enet.eurekaplatform.org/

Therapeutic trials actively recruiting

CC#189513: A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and IN combination with Pembrolizumab in Participants with KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma
Contact: Michelle Howell [email protected]
 
CC#20456: Precision Promise Platform Trial For Metastatic Pancreatic Cancer
Contact: Nancy Kaushal (415) 514-7633: [email protected] 
 
A021806: A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Contact: Bryan Le (415) 502-6313: [email protected]
 
CC#214514: A Phase 1b/2 Study of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients with Advanced Gastrointestinal Malignancies (HERKULES-3)
Contact: Marin Pollak (415) 476-7974: [email protected]
 
CC# 214515: An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination with Belzutifan in Multiple Solid Tumors
Contact: Karen Zhang (415) 502-1877: [email protected]
Not currently enrolling
 
CC#217015: Open-label, Multicenter, Phase 1b Clinical Trial to Evaluate the Safety and Efficacy of Autologous Claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma
Contact: Saba Saidi: [email protected]
 
CC#22454: A Phase 2 Basket Trial of Ulixertinib (BVD-523) in Combination with Hydroxychloroquine in Patients with Advanced Gastrointestinal Malignancies Harboring MAPK Pathway Mutations (BVD-523-HCQ)
Contact: Lauren Ford (415) 353-7284: [email protected]
Not yet enrolling
 
 
Pancreatic Non-Therapeutic Studies
 
CC#134510: GIMP: Tissue GIMP & Blood GIMP (Collisson)
Contact: Lauren Ford (415) 353-7284: [email protected]
 
CC#184519: Cell Free DNA and Imaging in Advanced Gastrointestinal Cancers
Contact: Lauren Ford (415) 353-7284: [email protected]
 
CC#204513: Exploring the Role of the Intestinal Microbiome in Mediating Treatment Outcomes for Patients with Locally Advanced or Metastatic Pancreatic Cancer
Contact: Banaz Shwan (415) 514-7285: [email protected]
 
CC#214513: Navigating a Whole Genome vs. Panel Approach for Patients with Advanced Pancreatic Cancer
Contact: Lauren Ford (415) 353-7284: [email protected]
 
CC#214516: NABPLAGEM Pancreatic Cancer Registry Protocol
Contact: Dr. Erica Tsang: [email protected]
 
 

CC#154520: Lifestyle and Outcomes after Gastrointestinal Cancer: A Prospective Cohort Study (LOGIC)
Contact: Dalila Stanfield (415) 476-2976: [email protected]
 
CC#19801: Digital Symptom Tracking, Patient Engagement and Quality of Life in Advanced Cancer (NOONA)
Contact: Ashna Sethi (415) 353-1745: [email protected] 
 
CC#21981: Understanding barriers to uptake of integrative oncology among Black patients with cancer
Contact: Dalila Stanfield (415) 476-2976: [email protected]

A021901: Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors
Contact: Bryan Le (415) 502-6313: [email protected]
 
CC#21709: An Open Label Phase 1A/B Study of MTL-CEBPA in Combination with a PD-1 Inhibitor (PEMBROLIZUMAB) in Adult Patients with Advanced Solid Tumors (TIMEPOINT)
Contact: Carolyn Bridgman (415) 514-7975: [email protected]
 
CC#194521: Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/Paraganglioma
Contact: Paige Steiding (415) 514-6314: [email protected]  
 
CC#214511: Electronic Patient Reported Outcomes in Patients with Gastrointestinal Cancers at Risk for Unplanned ED Visits and Hospitalizations
Contact: Param Kaur: [email protected]
 
CC#22457: Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with actinium Ac 225 dotatate (RYZ101) to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior treatment with 177Lu-DOTATATE or 177Lu-DOTATOC (177Lu-DOTATATE/TOC) (ACTION-1)
Contact: Paige Steiding (415) 514-6314: [email protected]  
 
CC#224512: The Optimization of Adaptive Text Messages to Improve Nutrition for Cancer Survivors (OATS)
Contact: Paige Steiding (415) 514-6314: [email protected]
 
CC#224514: A Phase 1b/2, Dose-escalation, Randomized, Multicenter Study of Maintenance Ivaltinostat plus Capecitabine or Capecitabine Monotherapy in Patients with Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on First Line FOLFIRINOX Chemotherapy
Contact: Alex Milloy (415) 502-3310: [email protected]
 
CC#204520: A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (DisTinGuish) - Part C
Contact: Alex Milloy (415) 502-3310: [email protected]
 
CC#20451: THREAD: A Phase I Trial of Trametinib and Hydroxychloroquine in Patients with Advanced Pancreatic Cancer
Contact: Alex Milloy (415) 502-3310: [email protected]
 
CC#224513: Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms (PanNEN)
Contact: Paige Steiding (415) 514-6314: [email protected]